
BIO-TECHNE CORP
TECHNASDAQTrading Snapshot
- Day Range
- $71.65 β $72.73
- 52-Week Range
- $43.20 β $72.39
- Volume
- $3.78B
- Avg Volume
- $4.81B
- Shares Outstanding
- 155.8M
- Next Earnings
- Sep 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.22B
- Last Q Revenue
- $311M
- P/E Ratio
- 104.3
- P/S Ratio
- 9.3x
- EPS (TTM)
- $0.69
- Dividend Yield
- 0.44%
Why Investors Own TECH
- βHigh-growth profile β revenue up -3.1% YoY with expanding US Equity exposure.
- βHealthy economics β 60% gross margin and 12% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIO-TECHNE CORP
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Is Bio-Techne (TECH) Above Fair Value After A 44% Return?
Bio-Techne stock has delivered a strong 44.2% return over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than as an obvious bargain. Over the last 12 months, Bio-Techne has returned 44.2%, which puts a clear spotlight on whether recent gains already reflect much of the good news in the price. Expectations around Bio-Techne's ability to grow revenue and sustain healthy cash flows...

JAZZ vs. TECH: Which Stock Is the Better Value Option?
JAZZ vs. TECH: Which Stock Is the Better Value Option?

Investorsβ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI [β¦]

2 S&P 500 Stocks to Keep an Eye On and 1 We Turn Down
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

1 Healthcare Stock Worth Your Attention and 2 We Question
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industryβs returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

Madison Mid Cap Fund Q2 2026 Portfolio Activity
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters.